


CLAIMS

1. A compound of formula (I),



Formula (I)

wherein

- B is a fused 6,5- or 6,6-heteroaromatic bicyclic ring, containing N and, optionally, one or two additional heteroatoms independently selected from N, O and S, which is optionally mono-, di or tri-substituted with a substituent selected from alkyl, alkoxy, OH, halo, CN, COOR₈, CONR₈R₉, CF₃ and NR₈R₉; wherein when B is a fused 6,5-heteroaromatic bicyclic ring, it is linked to -CONH-(CH₂)- *via* its 6-membered ring component;

- W, X, Y and Z are independently selected from C, N, O and S, such that the ring containing W, X, Y and Z is a five membered aromatic heterocycle;
- wherein,

- R₅, R₆ and R₇ are independently absent or independently selected from H, alkyl, halo, OH, aryl, heteroaryl, -NR₈R₉, CN, COOR₈, CONR₈R₉, -NR₈COR₉, CF₃, and R₁₆; wherein at least one of R₅, R₆ and R₇ is present and is independently selected from alkyl, halo, OH, aryl, heteroaryl, -NR₈R₉, CN, COOR₈, CONR₈R₉, -NR₈COR₉, CF₃ and R₁₆;

A is selected from aryl and heteroaryl;

R₈ and R₉ are independently selected from H and alkyl;

R₁₆ is a carbon-containing 3-, 4-, 5- or 6-membered monocyclic ring system which may be aromatic, saturated or unsaturated non-aromatic and which may optionally contain 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein the ring system R₁₆ is in turn optionally substituted with substituents selected from alkyl and oxo;

alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C_1 - C_{10}) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C_3 - C_{10}); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C_1 - C_6)alkoxy, OH, CN, CF_3 ,
 5 COOR10, CONR10R11, fluoro and NR10R11;

alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C_1 - C_6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C_3 - C_6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF_3 , COOR10,
 10 CONR10R11, fluoro and NR10R11;

aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, methylenedioxy, ethylenedioxy, OH, halo, CN, morpholinyl, piperidinyl, heteroaryl, $-(CH_2)_{0-3}$ -O-heteroaryl, aryl^b, -O-aryl^b, $-(CH_2)_{1-3}$ -
 15 aryl^b, $-(CH_2)_{1-3}$ -heteroaryl, -COOR10, -CONR10R11, $-(CH_2)_{1-3}$ -NR14R15, CF_3 and -NR10R11;

aryl^b is phenyl, biphenyl or naphthyl, which may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR10, -CONR10R11, CF_3 and NR10R11;

20 heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR8, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF_3 , halo, CN, aryl, morpholinyl, piperidinyl, $-(CH_2)_{1-3}$ -aryl, heteroaryl^b, -COOR10, -
 25 CONR10R11, CF_3 and -NR10R11;


heteroaryl^b is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR8, S and O; wherein heteroaryl^b may be optionally substituted with 1, 2 or 3 substituents independently selected
 30 from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, $-(CH_2)_{1-3}$ -aryl, -COOR10, -CONR10R11, CF_3 and NR10R11;

R10 and R11 are independently selected from H and alkyl or R10 and R11 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered

heterocyclic ring which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkyl, alkoxy, OH, F and CF₃;

- 5 R14 and R15 are independently selected from alkyl, aryl^b and heteroaryl^b; or R14 and R15 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring which may be saturated or unsaturated with 1 or 2 double bonds, and optionally may be oxo substituted;
- 10 and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof;

wherein the compound of formula (I) is not:



- 15 2. A compound according to claim 1, wherein B is a fused 6,6-heteroaromatic bicyclic ring, containing N and, optionally, one or two additional heteroatoms independently selected from N, O and S, which is optionally mono-, di or tri-substituted with a substituent selected from alkyl, alkoxy, OH, halo, CN, COOR₈, CONR₈R₉, CF₃ and NR₈R₉; wherein alkyl, alkoxy, R₈ and R₉ are as defined in claim 1.


20

3. A compound according to claim 2, wherein B is selected from optionally substituted quinoline, optionally substituted isoquinoline, optionally substituted quinoxaline, optionally substituted cinnoline, optionally substituted phthalazine, optionally substituted quinazoline, optionally substituted 1,2,4-benzotriazine, optionally substituted 1,2,3-benzotriazine, optionally substituted 1,7-naphthyridine, and optionally substituted 1,8-naphthyridine; wherein said optional substituents are selected from alkyl, alkoxy, OH, F, Cl, CN, COOR₈, CONR₈R₉, CF₃ and NR₈R₉; and wherein alkyl, alkoxy, R₈ and R₉ are as defined in claim 1.
- 25

4. A compound according to any one of claims 1 to 3, wherein B is selected from optionally mono-, di or tri-substituted isoquinolinyl wherein said optional substituent(s) are selected from alkyl, alkoxy, OH, F, Cl, CN, COOR₈, CONR₈R₉, CF₃ and NR₈R₉; and wherein alkyl, alkoxy, R₈ and R₉ are as defined in claim 1.

5


5. A compound according to claim 1, as defined by formula (II),



Formula (II)

wherein R₁, R₂ and R₃ are

- 10 (a) independently selected from H, alkyl, COOR₈, CONR₈R₉, OH, alkoxy, NR₈R₉, F and Cl; and wherein A, W, X, Y, Z, R₅, R₆, R₇, alkyl, alkoxy, R₈ and R₉ are as defined in claim 1; or
 (b) independently selected from H and alkyl.
6. A compound according to claim 1, wherein B is
- 15 (a) a fused 6,5- heteroaromatic bicyclic ring, containing N and, optionally, one or two additional heteroatoms independently selected from N, O and S, which is optionally mono-, di or tri-substituted with a substituent selected from alkyl, alkoxy, OH, halo, CN, COOR₈, CONR₈R₉, CF₃ and NR₈R₉; wherein alkyl, alkoxy, R₈ and R₉ are as defined in claim 1; or
 (b) selected from optionally substituted indole, optionally substituted indazole and
 20 optionally substituted 1H-pyrrolo[2,3-b]pyridine; wherein said optional substituents are selected from alkyl, alkoxy, OH, F, Cl, CN, COOR₈, CONR₈R₉, CF₃ and NR₈R₉; and wherein alkyl, alkoxy, R₈ and R₉ are as defined in claim 1; or
 (c) selected from optionally mono-, di or tri-substituted 1H-pyrrolo[2,3-b]pyridine, wherein said optional substituent(s) are selected from alkyl, alkoxy, OH, F, Cl, CN, COOR₈,
 25 CONR₈R₉, CF₃ and NR₈R₉; and wherein alkyl, alkoxy, R₈ and R₉ are as defined in claim 1.
7. A compound according to claim 1, as defined by formula (III),



Formula (III)

wherein R1 and R3 are

- (a) independently selected from H, alkyl, COOR8, CONR8R9, OH, alkoxy, NR8R9, F and Cl; and wherein A, W, X, Y, Z, R5, R6, R7, alkyl, alkoxy, R8 and R9 are as defined in claim 1; or
- (b) independently selected from H and alkyl; and wherein alkyl is as defined in claim 1.


8. A compound according to any one of claims 1 to 7, wherein at least one of R5, R6 and R7 is present and is independently selected from alkyl, halo, OH, aryl, heteroaryl and CF₃;
- 10 wherein alkyl, aryl and heteroaryl are as defined in claim 1.

9. A compound according to any one of claims 1 to 8 wherein W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a five-membered heterocycle selected from pyrrole, pyrazole, imidazole, 1, 2, 3-triazole and 1, 2, 4-triazole.


10. A compound according to any one of claims 1 to 9 wherein A is heteroaryl substituted by methyl, phenyl, morpholinyl, piperidinyl or -NR10R11 wherein phenyl is optionally substituted as defined in claim 1, and R10 and R11 are as defined in claim 1; or A is phenyl substituted by heteroaryl, -(CH₂)₁₋₃-heteroaryl or -(CH₂)₁₋₃-NR14R15, wherein heteroaryl, R14 and R15 are as defined in claim 1.

11. A compound according to claim 10 wherein A is

(a) selected from:



(b) selected from:



5

12. A compound according to claim 1, wherein said compound is

(a) selected from:

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (1-amino-
10 isoquinolin-6-ylmethyl)-amide;

2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid
(1-amino-isoquinolin-6-ylmethyl)-amide;

2,5-Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid
(1-amino-isoquinolin-6-ylmethyl)-amide;

15 1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic
acid (1-amino-isoquinolin-6-ylmethyl)-amide;

1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic
acid (1-amino-isoquinolin-6-ylmethyl)-amide;

- 3-Methyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 5 3-Isopropyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclobutyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Hydroxymethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic
10 acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyano-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 4-Methyl-2-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-thiazole-5-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 15 3-(3,5-Dimethyl-isoxazol-4-yl)-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-morpholin-4-yl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 5-Amino-1-(4-pyrazol-1-ylmethyl-benzyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 20 1-(6-Pyrrolidin-1-yl-pyridin-3-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-(5-methoxy-6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 25 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-phenyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Amino-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 30 3-Methoxymethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Difluoromethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;

- 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-thiophen-3-yl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 5-Amino-1-(4-pyrazol-1-ylmethyl-benzyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 5 1-(2-Pyrrolidin-1-yl-pyridin-4-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-(6-Ethoxy-pyridin-3-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 10 1-[2-(3,3-Difluoro-pyrrolidin-1-yl)-pyridin-4-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[6-(3,3-Difluoro-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[6-((R)-3-Methyl-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 15 1-[6-((S)-3-Methyl-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[6-((S)-3-Fluoro-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[6-((R)-3-Fluoro-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 20 1-[6-((S)-2-Methyl-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[6-((R)-2-Methyl-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 25 1-(2-Pyrrolidin-1-yl-pyrimidin-5-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-(5-Pyrrolidin-1-yl-pyrazin-2-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[2-((S)-3-Methyl-pyrrolidin-1-yl)-pyridin-4-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 30 1-[6-(3-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[6-((R)-3-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;

- 1-(6-Propoxy-pyridin-3-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-(5-Fluoro-6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 5 1-(6-Ethoxy-5-fluoro-pyridin-3-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-(4-Pyrazol-1-ylmethyl-benzyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 10 1-[4-(4-Cyano-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[4-(4-Carbamoyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-(6-Pyrazol-1-ylmethyl-pyridin-3-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 15 1-(2-Pyrazol-1-ylmethyl-thiazol-4-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 1-[2-(4-Methyl-pyrazol-1-ylmethyl)-thiazol-4-ylmethyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-{6-[(2-methoxy-ethyl)-methyl-amino]-pyridin-3-ylmethyl}-1H-pyrazole-20 4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-[6-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-3-ylmethyl]-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-(4-methoxy-6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 25 3-Cyclopropyl-1-(6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-(4-[1,2,3]triazol-1-ylmethyl-benzyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-(6-phenoxy-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic acid (1-30 amino-isoquinolin-6-ylmethyl)-amide;
- 1-(5-Chloro-6-ethoxy-pyridin-3-ylmethyl)-3-cyclopropyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
- 3-Cyclopropyl-1-(6-diethylamino-5-fluoro-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;

1-(5-Chloro-6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-3-cyclopropyl-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;

3-Amino-1-(6-ethoxy-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;

- 5 3-Amino-1-(6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-1H-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide;
and pharmaceutically acceptable salts and solvates thereof; or

(b) selected from:

- 10 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-pyrrolo[2,3-b]pyridin-5-ylmethyl)-amide;

1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-5-ylmethyl)-amide;

- 15 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-5-ylmethyl)-amide;

1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-pyrrolo[2,3-b]pyridin-5-ylmethyl)-amide;

1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-indol-5-ylmethyl)-amide;

- 20 3-Amino-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (1H-indazol-4-ylmethyl)-amide;

1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-indazol-4-ylmethyl)-amide;

and pharmaceutically acceptable salts and solvates thereof.

25

13. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 12 and a pharmaceutically acceptable carrier, diluent or excipient.

14. A compound as claimed in any one of claims 1 to 12 for use in medicine.

30

15. A compound as claimed in any one of claims 1 to 12 for use in a method of treatment of a disease or condition in which plasma kallikrein activity is implicated, wherein the disease or condition in which plasma kallikrein activity is implicated is

- (a) selected from impaired visual acuity, diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular
- 5 coagulation, cardiopulmonary bypass surgery and bleeding from post operative surgery; or
- (b) retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

16. The compound for use as claimed in claim 15, wherein the disease or condition in which
- 10 plasma kallikrein activity is implicated is hereditary angioedema.

17. The compound for use as claimed in claim 15, wherein the disease or condition in which plasma kallikrein activity is implicated is diabetic macular edema.